Clinical Trial

Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis

Study acronym: MIPSA
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 17, 2024 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.
Summary
The present study focuses on patients with Pseudomonas aeruginosa (PSA) sepsis. The aim of the present study is to find out whether the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype predominates in blood monocytes in critically ill patients with PSA-sepsis, and whether the severity of sepsis and outcome is associated with distinct monocyte phenotype and function.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2017-02-02.
Trial Details
NCT Number NCT03044223
Lead Sponsor University of Ulm
Conditions Pseudomonas Infections, Pseudomonas Septicemia, Pseudomonas; Pneumonia, Pseudomonal Bacteraemia, Pseudomonas Urinary Tract Infection, Pseudomonas Gastrointestinal Tract Infection, Sepsis, Sepsis, Severe +1 more
Enrollment 100 participants
Start Date 2014-08
Primary Completion 2025-11 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-01-17